Maslinic Acid Enhances Docetaxel Response in Human Docetaxel-Resistant Triple Negative Breast Carcinoma MDA-MB-231 Cells via Regulating MELK-FoxM1-ABCB1 Signaling Cascade

Docetaxel (DOC) is the most important chemotherapeutic drug for the treatment of triple negative breast cancer (TNBC); however, acquired drug resistance upon the long-term treatment limits its therapeutic effect. Maslinic acid (MA), a natural triterpene from Olea europaea L., attracts increasing int...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Ke, Zhu, Xue, Yin, Yongxiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7295941/
https://www.ncbi.nlm.nih.gov/pubmed/32581798
http://dx.doi.org/10.3389/fphar.2020.00835

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7295941/
https://www.ncbi.nlm.nih.gov/pubmed/32581798
http://dx.doi.org/10.3389/fphar.2020.00835

Ejemplares similares